Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envolimab + fruquintinib + oxaliplatin + tegafur
- Development stage
- Phase 3
- Lead developer
- AlphaMab Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
This combination therapy consists of the PD-L1 inhibitor envolimab, the VEGFR inhibitor fruquintinib, and the SOX chemotherapy regimen (oxaliplatin and tegafur). It is being investigated as a conversion therapy for patients with HER2-negative, unresectable locally advanced gastric cancer. Envolimab is a unique single-domain antibody (nanobody) targeting the PD-1/PD-L1 pathway, notable for its subcutaneous administration. Fruquintinib is a highly selective small-molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, which inhibits tumor angiogenesis. The addition of these targeted agents to the standard SOX chemotherapy backbone aims to increase the rate of successful surgical resection (R0 resection) by enhancing anti-tumor activity through synergistic immune checkpoint blockade, anti-angiogenesis, and cytotoxic effects.
- Other names
- envolimab + fruquintinib + SOX
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on envolimab + fruquintinib + oxaliplatin + tegafur.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envolimab + fruquintinib + oxaliplatin + tegafur.